1528636-29-4 Usage
Uses
Used in Pharmaceutical Industry:
((2R,3R,4S,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxy-3,4,5-tris-(trimethylsilyloxy)tetrahydro-2H-pyran-2-yl)methanol is used as a pharmaceutical compound for its potential therapeutic properties. Its complex structure may allow it to interact with biological targets in unique ways, offering new avenues for the treatment of various diseases and conditions.
Used in Chemical Research:
In the field of chemical research, ((2R,3R,4S,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxy-3,4,5-tris-(trimethylsilyloxy)tetrahydro-2H-pyran-2-yl)methanol serves as a subject of study for understanding the synthesis, properties, and potential applications of complex organic molecules. Its unique structure may provide insights into new chemical reactions and mechanisms.
Used in Industrial Applications:
((2R,3R,4S,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxy-3,4,5-tris-(trimethylsilyloxy)tetrahydro-2H-pyran-2-yl)methanol may be utilized in specific industrial processes, where its unique chemical properties can be harnessed for the development of new materials, catalysts, or other specialized products. Its potential uses in this area are dependent on further research and development to fully understand its capabilities and limitations.
Check Digit Verification of cas no
The CAS Registry Mumber 1528636-29-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,2,8,6,3 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1528636-29:
(9*1)+(8*5)+(7*2)+(6*8)+(5*6)+(4*3)+(3*6)+(2*2)+(1*9)=184
184 % 10 = 4
So 1528636-29-4 is a valid CAS Registry Number.
1528636-29-4Relevant academic research and scientific papers
AN EFFICIENT PROCESS FOR THE PREPARATION OF ERTUGLIFLOZIN L-PYROGLUTAMIC ACID AND INTERMEDIATES THEREOF
-
, (2021/07/10)
The present invention relates to an efficient process for the preparation of Ertugliflozin L-pyroglutamic acid of formula (I) and intermediate thereof, in environment friendly conditions. The present invention further relates to a process for the preparation of substantially pure intermediate of formula (IV).
Development of an early-phase bulk enabling route to sodium-dependent glucose cotransporter 2 inhibitor ertugliflozin
Bernhardson, David,Brandt, Thomas A.,Hulford, Catherine A.,Lehner, Richard S.,Preston, Brian R.,Price, Kristin,Sagal, John F.,Pierre, Michael J. St.,Thompson, Peter H.,Thuma, Benjamin
, p. 57 - 65 (2014/05/20)
The development and optimization of a scalable synthesis of sodium-dependent glucose cotransporter 2 inhibitor, ertugliflozin, for the treatment of type-2 diabetes is described. Highlights of the chemistry are a concise, four-step synthesis of a structurally complex API from known intermediate 4 via persilylation-selective monodesilylation, primary alcohol oxidation, aldol-crossed-Cannizzaro reaction, and solid-phase acid-catalyzed bicyclic ketal formation. The final API was isolated as the Lpyroglutamic acid cocrystal.
